R266
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.490
- PROTEIN_SECRETION+0.410
- ANDROGEN_RESPONSE+0.380
- TGF_BETA_SIGNALING+0.360
- MYC_TARGETS_V1+0.340
- HYPOXIA+0.330
- MTORC1_SIGNALING+0.320
- P53_PATHWAY+0.300
- MITOTIC_SPINDLE+0.290
- NOTCH_SIGNALING+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.340
- PANCREAS_BETA_CELLS-0.300
- APICAL_SURFACE-0.280
- ALLOGRAFT_REJECTION-0.240
- INFLAMMATORY_RESPONSE-0.240
- INTERFERON_GAMMA_RESPONSE-0.210
- IL6_JAK_STAT3_SIGNALING-0.180
- HEDGEHOG_SIGNALING-0.150
- KRAS_SIGNALING_DN-0.130
- CHOLESTEROL_HOMEOSTASIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R205 | — | — | 0.819 |
| 2 | SRR12202472 | — | — | 0.799 |
| 3 | TCGA-4Z-AA7Y-01A-11R-A39I-07 | — | — | 0.795 |
| 4 | SRR13311164 | — | — | 0.785 |
| 5 | DRR168536 | — | — | 0.756 |
| 6 | SRR23303753 | — | — | 0.752 |
| 7 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.747 |
| 8 | MNG666 | — | — | 0.734 |
| 9 | SRR23303771 | — | — | 0.732 |
| 10 | SRR12696786 | — | — | 0.732 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |